Journal of the Neurological Sciences
Volume 298, Issue 1 , Pages 153-157 , 15 November 2010

Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: A nationwide study

  • Amytis Towfighi

      Affiliations

    • Department of Neurology, University of Southern California, USA
    • Corresponding Author InformationCorresponding author. 1510 San Pablo Street, HCC 643, Los Angeles, CA 90033, USA. Tel.: +1 323 491 6495; fax: +1 562 401 7615.
    • ,
  • Daniela Markovic

      Affiliations

    • Department of Biomathematics, University of California at Los Angeles, USA
    • ,
  • Bruce Ovbiagele

      Affiliations

    • Department of Neurology, University of California at Los Angeles, USA

Received 26 March 2010 ,Revised 19 July 2010 ,Accepted 19 July 2010.

References 

  1. Hankey G. Is homocysteine a causal and treatable risk factor for stroke?. Lancet Neurol. 2007;6(9):751–752
  2. Potter K, Hankey GJ, Green DJ, Eikelboom JW, Arnolda LF. Homocysteine or renal impairment: which is the real cardiovascular risk factor?. Arterioscler Thromb Vasc Biol. 2008;28(6):1158–1164
  3. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565–575
  4. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296(22):2720–2726
  5. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578–1588
  6. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300(7):795–804
  7. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299(17):2027–2036
  8. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–1577
  9. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876–1882
  10. Hankey GJ, Algra A, Chen C, et al. VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). Int J Stroke. 2007;2(2):144–150
  11. Bostom AG, Carpenter MA, Kusek JW, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J. 2006;152(3):e1–e7448
  12. Spence J. Homocysteine-lowering therapy: a role in stroke prevention?. Neurol. 2007;6(9):830–838
  13. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke. 2005;36(11):2404–2409
  14. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. Vital Health Stat 1. 1994;1(32):1–407
  15. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151(2):282–287
  16. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340(19):1449–1454
  17. McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr. 2007;86(5):1563S–1568S
  18. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266
  19. Kasiman K, Eikelboom JW, Hankey GJ, et al. Ethnicity does not affect the homocysteine-lowering effect of B-vitamin therapy in Singaporean stroke patients. Stroke. 2009;40(6):2209–2211
  20. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2002;156(12):1105–1113
  21. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition Examination Survey, 1988-1994. Stroke. 1998;29(12):2473–2477
  22. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol. 1997;54(10):1276–1282
  23. Mizrahi EH, Noy S, Sela BA, Fleissig Y, Arad M, Adunsky A. Further evidence of interrelation between homocysteine and hypertension in stroke patients: a cross-sectional study. Isr Med Assoc J. 2003;5(11):791–794
  24. Al-Delaimy WK, Rexrode KM, Hu FB, et al. Folate intake and risk of stroke among women. Stroke. 2004;35(6):1259–1263
  25. He K, Merchant A, Rimm EB, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke. 2004;35(1):169–174
  26. Van Guelpen B, Hultdin J, Johansson I, et al. Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake. Stroke. 2005;36(7):1426–1431
  27. Bazzano LA, He J, Ogden LG, et al. Dietary intake of folate and risk of stroke in US men and women: NHANES I Epidemiologic Follow-up Study. National Health and Nutrition Examination Survey. Stroke. 2002;33(5):1183–1188
  28. Weng LC, Yeh WT, Bai CH, et al. Is ischemic stroke risk related to folate status or other nutrients correlated with folate intake?. Stroke. 2008;39(12):3152–3158
  29. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40(4):1365–1372
  30. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5mg daily. Am J Nephrol. 1999;19(3):405–410
  31. Engstad T, Bonaa KH, Viitanen M. Validity of self-reported stroke: The Tromso Study. Stroke. 2000;31(7):1602–1607
  32. O'Mahony PG, Dobson R, Rodgers H, James OF, Thomson RG. Validation of a population screening questionnaire to assess prevalence of stroke. Stroke. 1995;26(8):1334–1337
  33. Li Z, Sun L, Zhang H, et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. Stroke. 2003;34(9):2085–2090
  34. Ay H, Arsava EM, Tokgozoglu SL, Ozer N, Saribas O. Hyperhomocysteinemia is associated with the presence of left atrial thrombus in stroke patients with nonvalvular atrial fibrillation. Stroke. 2003;34(4):909–912
  35. Loffredo L, Violi F, Fimognari FL, et al. The association between hyperhomocysteinemia and ischemic stroke in patients with non-valvular atrial fibrillation. Haematologica. 2005;90(9):1205–1211
  36. Poli D, Antonucci E, Cecchi E, et al. Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke. 2005;36(10):2159–2163

☆ Dr. Towfighi presented these findings at a platform presentation at the 7th International Conference on Homocysteine Metabolism in Prague, Czech Republic in June 2009.

PII: S0022-510X(10)00336-9

doi: 10.1016/j.jns.2010.07.013

Journal of the Neurological Sciences
Volume 298, Issue 1 , Pages 153-157 , 15 November 2010

Article Tools

* Image Usage & Resolution